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*APOE4*, a form of the human apolipoprotein E gene, is a genetic risk factor for Alzheimer's disease (AD) and is also associated with other forms of neuropathology. APOE4 is thought to compromise the blood-brain barrier (BBB), but the underlying mechanisms have been unclear. Bell et al. addressed this issue by studying the brain microvasculature in several strains of genetically engineered mice: one lacking the mouse *Apoe* gene, and others expressing human *APOE2*, *APOE3* or *APOE4*. They found that *Apoe^−/−^* and *APOE4* mice, but not *APOE2* or *APOE3* mice, had severe BBB defects that were caused by defective regulation of the levels of cyclophilin A (CypA). Increased levels of CypA in *Apoe^−/−^* and *APOE4* mice caused activation of NFκB, which in turn increased the expression and activation of MMP-9 in pericytes, which surround the microvasculature. Higher levels of active MMP-9 were shown to compromise BBB integrity in *Apoe^−/−^* and *APOE4* mice; notably, effects on the vasculature preceded neurodegeneration. Genetic ablation or pharmacological inhibition of CypA restored the BBB, as did an MMP-9 inhibitor. These results broaden our understanding of how APOE4 might compromise the BBB and thereby contribute to AD and other neuropathologies.
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